Tumor necrosis is significantly associated with reduced recurrence-free survival after curative resection of gastrointestinal stromal tumors.

Tyler, Robert William, Davies, Emma, Tan, Dominic, Hodson, James, Taniere, Phillipe, Thway, Khin, Jafri, Mariam, Almond, Max, Ford, Samuel, Strauss, Dirk, Hayes, Andrew, Smith, Myles and Desai, Anant (2020) Tumor necrosis is significantly associated with reduced recurrence-free survival after curative resection of gastrointestinal stromal tumors. Journal of surgical oncology. ISSN 1096-9098.

[img]
Preview
Text
jso.26294.pdf

Download (700kB) | Preview
Official URL: https://onlinelibrary.wiley.com/doi/10.1002/jso.26...

Abstract

BACKGROUND OBJECTIVES

The impact of tumor necrosis as a prognostic factor in gastrointestinal stromal tumor (GISTs) is still debated. The objective was to determine whether tumor necrosis is an independent risk factor for survival in patients with GISTs.

METHODS

Patients undergoing surgery for primary GIST from March 2003 to October 2018 at two sarcoma referral centers were retrospectively identified. Patients who received neoadjuvant imatinib were excluded. Multivariable Cox regression models were produced, to assess whether tumor necrosis was an independent predictor of either overall or recurrence-free survival.

RESULTS

Forty-one out of 195 (21.0%) patients had tumor necrosis. Tumor necrosis was associated with a significantly higher modified National Institute of Health risk score, with 29 out of 41 (70.7%) patients with necrosis classified as high risk, compared to 52 out of 153 (34.0%) without (p < .001). Tumor necrosis was found to be independently predictive of recurrence-free survival (hazard ratio: 5.26, 95% CI: 2.62-10.56, p < .001) on multivariable analysis. At 5 years, 44.3% of patients with necrosis had either died or developed recurrence, compared to 9.9% of those without.

CONCLUSION

Tumor necrosis is an independent predictor of recurrence-free survival in patients with operable GISTs. It should be routinely reported by pathologists, and used by clinicians when counseling patients and deciding on adjuvant therapy.

Item Type: Article
Subjects: QZ Pathology. Oncology
Divisions: Planned IP Care > Oncology and Clinical Haematology
Related URLs:
Depositing User: Mr Philip O'Reilly
Date Deposited: 20 Nov 2020 15:25
Last Modified: 20 Nov 2020 15:25
URI: http://www.repository.uhblibrary.co.uk/id/eprint/3688

Actions (login required)

View Item View Item